1.Advances in Novel Ocular Drug Delivery Systems
Jufang LYU ; Fen CHEN ; Yibin YU
Chinese Journal of Modern Applied Pharmacy 2024;41(3):389-407
		                        		
		                        			
		                        			The ocular bioavailability of traditional ophthalmic preparations is relatively low, and it is difficult to have a satisfactory therapeutic effect on ocular diseases, which is mainly due to the difficulty of traditional ophthalmic preparations to pass through many physiological barriers in the eye and the short residence time of the preparations in the eye. In order to improve the ocular bioavailability of drugs and reduce the adverse drug reaction to ocular tissues, some novel drug delivery systems, such as nanoparticles, microspheres, and in situ gels, have been employed to develop ophthalmic preparations, and have attracted increasing attention of researchers. In terms of the rapid development of ocular drug delivery systems, recent advances in ocular drug delivery systems are summarized in this paper. Firstly, ocular structure and physiological barriers which restrict drugs into the eye are introduced. Secondly, novel ocular drug delivery systems, including nanoparticles, liposomes, lipid nanoparticles, microspheres, and in situ gels are introduced. Finally, the future prospects and crucial problems of ocular drug delivery systems in clinical treatment are focused on.
		                        		
		                        		
		                        		
		                        	
2.Effect of prehospital multimodal prehabilitation on preoperative function and postoperative recovery in patients with gastrointestinal malignant tumors
Rui TAI ; Jufang SUN ; Ying LIN ; Yaqing ZHANG ; Chen HUANG ; Fang FANG
Journal of Shanghai Jiaotong University(Medical Science) 2024;44(10):1229-1234
		                        		
		                        			
		                        			Objective·To explore the effect of a prehospital multimodal prehabilitation program on the preoperative functional status and postoperative recovery of patients with gastrointestinal malignant tumors.Methods·A total of 78 patients with gastrointestinal malignant tumors,hospitalized in Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine from June to December 2023,were enrolled.They were divided into the standard group(SD group,n=40)and the prehospital multimodal prehabilitation group(PMP group,n=38)by using random number table.From the time the operation was agreed upon by both the doctor and patient to the day before the operation,the SD group followed the routine preoperative guidance,while the PMP group received a home-based prehospital multimodal prehabilitation program.The general data of patients were collected,and the six-minute walk distance(6MWD)was compared between the two groups at baseline and on the day before operation.The length of postoperative hospitalization,time to first flatus,time to first ambulation,time to first oral intake,drainage removal time and postoperative complication rate were also compared between the two groups.Results·There was no difference in general data and duration of preoperative intervention of patients between the two groups.At baseline,there was no significant difference in 6MWD between the two groups.On the day before operation,the 6MWD in the PMP group was higher than that in the SD group(P=0.016).Changes in 6MWD in the PMP group were significantly higher compared to SD group during the preoperative period,with values of(23.42±13.59)m vs.(-3.75±12.08)m(P<0.001).Time to first flatus,time to first ambulation and time to first oral intake in the PMP group were earlier than those in the SD group(P<0.05).However,there was no significant difference in drainage removal time,postoperative hospitalization and postoperative complication rate between the two groups(P>0.05).Conclusion·Prehospital multimodal prehabilitation can improve the preoperative function and accelerate the postoperative recovery in patients with gastrointestinal malignancies.
		                        		
		                        		
		                        		
		                        	
3.Associations of serum amyloid A with the overall burden of cerebral small vessel disease and early neurological deterioration in patients with acute ischemic stroke
International Journal of Cerebrovascular Diseases 2024;32(8):591-596
		                        		
		                        			
		                        			Objective:To investigate the associations of serum amyloid A (SAA) with the overall burden of cerebral small vessel disease (CSVD) and early neurological deterioration (END) in patients with acute ischemic stroke (AIS).Methods:Patients with AIS admitted to the Department of Neurology, Baise People's Hospital from August 2021 to August 2023 were included retrospectively. END was defined as an increase of ≥2 in the National Institutes of Health Stroke Scale (NIHSS) score within 72 hours of onset compared to the admission score. The baseline data of patients with different CSVD burden group, as well as END and non-END groups were compared. Multivariate logistic regression analysis was used to determine the independent correlation factors for the overall burden of CSVD and END. Results:A total of 131 patients with AIS were enrolled, including 78 males (59.54%), aged 63.80±7.34 years. Sixteen patients (12.2%) were in the CSVD overall burden 0-point group, 58 (44.3%) in the 1-point group, 29 (22.1%) in the 2-point group, 22 (16.8%) in the 3-point, and 6 (4.6%) in the 4-point group; and 52 (39.7%) experienced END. There were significant differences in age, diabetes, smoking, drinking, NIHSS score at admission, total burden of CSVD, previous stroke or transient ischemic attack history, homocysteine, fasting blood glucose, uric acid and SAA between the END group and the non-END group (all P<0.05). Multivariate logistic regression analysis showed that SAA was an independent risk factor for END (odds ratio 4.703, 95% confidence interval 2.492-8.875; P<0.001). There was a significant difference in SAA among different CSVD burden groups ( P<0.001), and SAA increased with the increase of CSVD burden score. Ordinal multivariate logistic regression analysis showed that SAA was independently correlated with the overall burden of CSVD (odds ratio 4.576, 95% confidence interval 2.542-8.239; P<0.001). Conclusion:SAA is associated with the overall burden of CSVD and END in patients with AIS.
		                        		
		                        		
		                        		
		                        	
4.China guideline for liver cancer screening (2022, Beijing)
Jie HE ; Wanqing CHEN ; Hongbing SHEN ; Ni LI ; Chunfeng QU ; Jufang SHI ; Feng SUN ; Jing JIANG ; Guangwen CAO ; Guihua ZHUANG ; Ji PENG
Journal of Clinical Hepatology 2022;38(8):1739-1772
		                        		
		                        			
		                        			 In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China's national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China. 
		                        		
		                        		
		                        		
		                        	
5.China guideline for liver cancer screening (2022, Beijing)
Jie HE ; Wanqing CHEN ; Hongbing SHEN ; Ni LI ; Chunfeng QU ; Jufang SHI ; Feng SUN ; Jing JIANG ; Guangwen CAO ; Guihua ZHUANG ; Ji PENG
Chinese Journal of Digestive Surgery 2022;21(8):971-996
		                        		
		                        			
		                        			In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous explora-tion. This guideline was commissioned by the Bureau of Disease Control and Prevention of the National Health Commission. The National Cancer Center of China initiated the guideline develop-ment and convened a multidisciplinary expert panel and working group. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China′s national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help to standardize the practice of liver cancer screening in China.
		                        		
		                        		
		                        		
		                        	
6.Probiotics improves abnormal behavior and hippocampal injury in pregnant-stressed offspring rats.
Zhongjun HUANG ; Bin ZHANG ; Libin LIAO ; Jie CHEN ; Ruping ZHENG ; Deyang CAI ; Jufang HUANG
Journal of Central South University(Medical Sciences) 2022;47(4):443-452
		                        		
		                        			OBJECTIVES:
		                        			During pregnancy, pregnant women are prone to stress reactions due to external stimuli, affecting their own health and fetal development. At present, there is no good treatment for the stress reactions from pregnant women during pregnancy. This study aims to explore the effect of probiotics on abnormal behavior and hippocampal injury in pregnant stressed offspring.
		                        		
		                        			METHODS:
		                        			SD pregnant rats were divided into a control group, a stress group, and a probiotics group, with 6 rats in each group. The control group was untreated; the stress group was given restraint stress on the 15th-20th day of pregnancy; the probiotics group was given both bifidobacterium trisporus capsules and restraint stress on the 15th-20th day of pregnancy, and the offspring continued to be fed with probiotics until 60 days after birth (P60). The offspring rats completed behavioral tests such as the open field test, the elevated plus maze test, the new object recognition test, and the barnes maze test at 60-70 d postnatally. Nissl's staining was used to reflect the injury of hippocampal neurons; immunohistochemical staining was used to detect the expression of microglia marker ionized calcium binding adapter molecule 1 (IBA-1) which can reflect microglia activation; ELISA was used to detect the content of plasma TNF-α and IL-1β; Western blotting was used to detect the expression of Bax, Bcl-2, and caspase-3.
		                        		
		                        			RESULTS:
		                        			The retention time of offspring rats in the stress group in the central area of the open field was significantly less than that in the control group (P<0.01), and the retention time of offspring rats in the probiotic group in the central area of the open field was significantly more than that in the stress group (P<0.05). The offspring rats in the stress group stayed in the open arm for a shorter time than the control group (P<0.05) and entered the open arm less often than the control group (P<0.01); the offspring rats in the probiotic group stayed in the open arm for a longer time than the stress group and entered the open arm more often than the stress group (both P<0.05). The discrimination ratio for new to old objects in the offspring rats of the stress group was significantly lower than that of the control group (P<0.01), and the discrimination ratio for new to old objects in the offspring rats of the probiotic group was significantly higher than that of the stress group (P<0.05). The offspring rats in the stress group made significantly more mistakes than the control group (P<0.05), and the offspring rats in the probiotic group made significantly fewer mistakes than the stress group (P<0.05). Compared with the control group, the numbers of Nissl bodies in CA1, CA3, and DG area were significantly reduced in the offspring rats of the stress group (all P<0.001), the number of activated microglia in DG area of hippocampus was significantly increased (P<0.01), the contents of TNF-α and IL-1β in peripheral blood were significantly increased (P<0.05 or P<0.01), the protein expression level of Bcl-2 was significantly down-regulated, and the protein expression levels of Bax and caspase-3 were significantly up-regulated (all P<0.001). Compared with the stress group, the numbers of Nissl bodies in CA1, CA3, and DG area were significantly increased in the probiotic group offspring rats (P<0.001, P<0.01, P<0.05), the number of activated microglia in the DG area of hippocampus was significantly reduced (P<0.05), and the TNF-α and IL-1β levels in peripheral blood were significantly decreased (both P<0.05), the protein expression level of Bcl-2 was significantly up-regulated, and the protein expression levels of Bax and caspase-3 were significantly down-regulated (all P<0.001).
		                        		
		                        			CONCLUSIONS
		                        			Probiotic intervention partially ameliorated anxiety and cognitive impairment in rats offspring of pregnancy stress, and the mechanism may be related to increasing the number of neurons, inhibiting the activation of hippocampal microglia, and reducing inflammation and apoptosis.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Caspase 3/metabolism*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Hippocampus/physiopathology*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Probiotics/therapeutic use*
		                        			;
		                        		
		                        			Proto-Oncogene Proteins c-bcl-2/metabolism*
		                        			;
		                        		
		                        			Rats
		                        			;
		                        		
		                        			Stress, Psychological/therapy*
		                        			;
		                        		
		                        			Tumor Necrosis Factor-alpha/metabolism*
		                        			;
		                        		
		                        			bcl-2-Associated X Protein/metabolism*
		                        			
		                        		
		                        	
7.Access to liver cancer screening and surveillance in populations in China: an exploratory analysis
Jufang SHI ; Mengdi CAO ; Xinxin YAN ; Maomao CAO ; Yuting WANG ; Yanjie LI ; Xin WANG ; Jibin LI ; Ni LI ; Chunfeng QU ; Wanqing CHEN
Chinese Journal of Epidemiology 2022;43(6):906-914
		                        		
		                        			
		                        			Objective:To systematically quantify the access to screening and surveillance service of liver cancer in populations in China, especially a series of sub-indicators of the availability.Methods:Following the specific indicators applied by the International Agency for Research on Cancer in the session of availability and use of screening practices in several cancer screening handbooks, information about the access/availability of liver cancer screening and surveillance in population in China were collected; the indicators included local policies and guidelines, procedures most commonly used or recommended, population coverage and participation rate, compliance and related factors, treatment rate, acceptability, equity and others. Systematic review approach was used, combined with searching core literatures/monograph, websites of governments and available program reports, for a systematic analysis on the access to liver cancer screening and surveillance in populations in China.Results:A total of 34 journal articles were included from the systematic review and most of which were about the participation of secondary liver screening or surveillance compliance; additional information were mainly obtained from the other sources. Overall, there were clearly recommended screening and surveillance procedures for liver cancer in the three major cancer screening programs funded by the central government of China. It was estimated that 0.09% of the population aged 35-74 years were covered by liver cancer screening in 2019 in China. The overall participation rates of secondary screening ranged from 37.5% to 62.3% in three major programs, the median compliance rate of surveillance was reported as 26.9% ( Q1, Q3: 23.5%, 41.0%) in the 6 included studies. Two studies reported the factors affecting the participation and compliance. A large-scale multicenter analysis showed that the subject acceptability to alpha fetoprotein test combined with ultrasound screening was as high as 99.3% in high-risk population in urban area. The treatment rate of liver cancer founded by screening, surveillance or follow-up was estimated to be >90% in rural population. No studies of equity were obtained via the systematic review. Conclusions:The public health service programs in China all recommend specific procedures for liver cancer screening in general population and surveillance for high-risk individuals. However, the overall availability needs to be improved, particularly in the indicator of population coverage. Participation rates of screening and compliance rates of surveillance varied among the included programs and the studies, suggesting that the influencing factors need to be further identified. The relatively high subject acceptability suggests the potential demands for screening service. More efforts are needed to address the access to screening and surveillance of liver cancer in populations in China.
		                        		
		                        		
		                        		
		                        	
8.China guideline for liver cancer screening (2022, Beijing)
Jie HE ; Wanqing CHEN ; Hongbing SHEN ; Ni LI ; Chunfeng QU ; Jufang SHI ; Feng SUN ; Jing JIANG ; Guangwen CAO ; Guihua ZHUANG ; Ji PENG
Chinese Journal of Oncology 2022;44(8):779-814
		                        		
		                        			
		                        			In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China′s national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China.
		                        		
		                        		
		                        		
		                        	
9.China guideline for liver cancer screening (2022, Beijing)
Jie HE ; Wanqing CHEN ; Hongbing SHEN ; Ni LI ; Chunfeng QU ; Jufang SHI ; Feng SUN ; Jing JIANG ; Guangwen CAO ; Guihua ZHUANG ; Ji PENG
Chinese Journal of Oncology 2022;44(8):779-814
		                        		
		                        			
		                        			In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China′s national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China.
		                        		
		                        		
		                        		
		                        	
10.Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program
Zheng WU ; Fengwei TAN ; Zhuoyu YANG ; Fei WANG ; Wei CAO ; Chao QIN ; Xuesi DONG ; Yadi ZHENG ; Zilin LUO ; Liang ZHAO ; Yiwen YU ; Yongjie XU ; Jiansong REN ; Jufang SHI ; Hongda CHEN ; Jiang LI ; Wei TANG ; Sipeng SHEN ; Ning WU ; Wanqing CHEN ; Ni LI ; Jie HE
Chinese Medical Journal 2022;135(11):1331-1339
		                        		
		                        			
		                        			Background::Non-smokers account for a large proportion of lung cancer patients, especially in Asia, but the attention paid to them is limited compared with smokers. In non-smokers, males display a risk for lung cancer incidence distinct from the females—even after excluding the influence of smoking; but the knowledge regarding the factors causing the difference is sparse. Based on a large multicenter prospective cancer screening cohort in China, we aimed to elucidate the interpretable sex differences caused by known factors and provide clues for primary and secondary prevention.Methods::Risk factors including demographic characteristics, lifestyle factors, family history of cancer, and baseline comorbidity were obtained from 796,283 Chinese non-smoking participants by the baseline risk assessment completed in 2013 to 2018. Cox regression analysis was performed to assess the sex difference in the risk of lung cancer, and the hazard ratios (HRs) that were adjusted for different known factors were calculated and compared to determine the proportion of excess risk and to explain the existing risk factors.Results::With a median follow-up of 4.80 years, 3351 subjects who were diagnosed with lung cancer were selected in the analysis. The lung cancer risk of males was significantly higher than that of females; the HRs in all male non-smokers were 1.29 (95% confidence interval [CI]: 1.20-1.38) after adjusting for the age and 1.38 (95% CI: 1.28-1.50) after adjusting for all factors, which suggested that known factors could not explain the sex difference in the risk of lung cancer in non-smokers. Known factors were 7% (|1.29-1.38|/1.29) more harmful in women than in men. For adenocarcinoma, women showed excess risk higher than men, contrary to squamous cell carcinoma; after adjusting for all factors, 47% ([1.30-1.16]/[1.30-1]) and 4% ([7.02-6.75]/[7.02-1])) of the excess risk was explainable in adenocarcinoma and squamous cell carcinoma. The main causes of gender differences in lung cancer risk were lifestyle factors, baseline comorbidity, and family history.Conclusions::Significant gender differences in the risk of lung cancer were discovered in China non-smokers. Existing risk factors did not explain the excess lung cancer risk of all non-smoking men, and the internal causes for the excess risk still need to be explored; most known risk factors were more harmful to non-smoking women; further exploring the causes of the sex difference would help to improve the prevention and screening programs and protect the non-smoking males from lung cancers.
		                        		
		                        		
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail